IQVIA, a leading healthcare research company, recently released a new report, “Advancing Biosimilar Sustainability in Europe,” which examines the status of biosimilars within the current health models of multiple European countries and includes prescriptive elements about how biosimilars might continue their growth in European markets.
Biosimilars in Europe have thus far been ahead of the U.S. market with 50 approved biosimilars compared to just 12 FDA-approved American products. One benefit as American biosimilar stakeholders attempt to catch up is the opportunity to observe what is working and what isn’t in European markets, and this latest study further builds on that base of knowledge.
A few key findings of the report:
- “Biosimilars are a key means to alleviate financial challenges faced by many stakeholders in the currently constrained European budgetary environment.
- “Elements of biosimilar sustainability represent the needs of all stakeholders including patients, physicians, payers and manufacturers and support the healthy functioning of the marketplace for medicines.
- “Based on sustainable policies currently in place in Europe, a set of best practices can be leveraged to ensure long-term sustainability of the biosimilars market, while additionally fulfilling the needs of all stakeholders.”
Click here to read the full report.
